Covered recipient · General Payments record
T HEMANTH RAO
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$5.57
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $5.57 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Retrophin, Inc. | $5.57 | 2 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
T HEMANTH RAO
NPI 1023070745 · CMS profile ID 677428
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
CHARLOTTE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023070745?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023070745?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023070745?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- T HEMANTH RAO, NPI 1023070745, CMS profile ID 677428, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1023070745?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $5.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Retrophin, Inc. | $0.83 | 02/12/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701819007 | CMS |
| Retrophin, Inc. | $4.74 | 02/12/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701819009 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2022
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $590,566.02 | 42 |
| PY2024 | Principal investigator | $757,803.02 | 58 |
| PY2023 | Principal investigator | $705,507.39 | 95 |
| PY2022 | Recipient | $3,120.00 | 1 |
| PY2022 | Principal investigator | $783,014.66 | 39 |
| PY2021 | Principal investigator | $424,194.70 | 79 |
| PY2020 | Principal investigator | $514,521.07 | 71 |
| PY2019 | Principal investigator | $249,052.37 | 33 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
79 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | UCB SA | $576.00 | 12/20/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844229819 |
| Principal investigator 1 | UCB SA | $318.00 | 12/20/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844229999 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,550.00 | 12/14/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | SECOND PHASE III IN RMS | No dispute reported | 06/30/2026 | 836030115 |
| Principal investigator 1 | Roche Products Limited | $1,850.00 | 11/29/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030103 |
| Principal investigator 1 | Roche Products Limited | $925.00 | 11/29/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030109 |
| Principal investigator 1 | UCB SA | $4,768.00 | 11/08/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844231847 |
| Principal investigator 1 | UCB SA | $3,525.00 | 11/01/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP | No dispute reported | 06/30/2026 | 844228019 |
| Principal investigator 1 | UCB SA | $788.00 | 10/29/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP | No dispute reported | 06/30/2026 | 844227847 |
| Principal investigator 1 | UCB SA | $1,900.00 | 10/25/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A. | A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY | No dispute reported | 06/30/2026 | 844227813 |
| Principal investigator 1 | Roche Products Limited | $700.00 | 10/21/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030091 |
| Principal investigator 1 | UCB SA | $10,078.00 | 10/21/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844227501 |
| Principal investigator 1 | Roche Products Limited | $1,850.00 | 10/18/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030097 |
| Principal investigator 1 | Roche Products Limited | $2,750.00 | 10/14/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030085 |
| Principal investigator 1 | H. Lundbeck A S | $106.25 | 10/13/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE OF PA | A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY | No dispute reported | 06/30/2026 | 853090271 |
| Principal investigator 1 | UCB SA | $3,012.00 | 10/11/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844227477 |
| Principal investigator 1 | UCB SA | $658.00 | 10/11/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844227481 |
| Principal investigator 1 | UCB SA | $4,518.00 | 10/11/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844227483 |
| Principal investigator 1 | UCB SA | $574.00 | 10/11/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844227485 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $69,923.36 | 09/29/2021 | Non-covered Recipient Entity NEUROLOGICAL INSTITUTE | AN OPEN-LABEL MULTICENTER STUDY TO ASSESS RESPONSE TO COVID-19 VACCINE IN PARTICIPANTS WITH MULTIPLE SCLEROSIS TREATED WITH OFATUMUMAB 20 MG SUBCUTANEOUSLY | No dispute reported | 06/30/2026 | 800636529 |
| Principal investigator 1 | Roche Products Limited | $5,500.00 | 09/28/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | SATRALIZUMAB OPEN LABEL TREATMENT STUDY IN PATIENTS WITH NMOSD | No dispute reported | 06/30/2026 | 836030013 |
| Principal investigator 1 | Roche Products Limited | $2,500.00 | 09/28/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | SATRALIZUMAB OPEN LABEL TREATMENT STUDY IN PATIENTS WITH NMOSD | No dispute reported | 06/30/2026 | 836030019 |
| Principal investigator 1 | Roche Products Limited | $4,000.00 | 09/28/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | SATRALIZUMAB OPEN LABEL TREATMENT STUDY IN PATIENTS WITH NMOSD | No dispute reported | 06/30/2026 | 836030025 |
| Principal investigator 1 | H. Lundbeck A S | $1,391.25 | 09/09/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE OF PA | A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY | No dispute reported | 06/30/2026 | 853090141 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $29,349.00 | 09/07/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, P.A. | SECOND PHASE III IN RMS | No dispute reported | 06/30/2026 | 836030133 |
| Principal investigator 1 | H. Lundbeck A S | $500.00 | 08/25/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE OF PA | A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY | No dispute reported | 06/30/2026 | 853090101 |
| Principal investigator 1 | H. Lundbeck A S | $1,876.25 | 08/19/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE OF PA | A CLINICAL STUDY OF PATIENTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION TO ASSESS SUSTAINED EFFECTS OF DROXIDOPA THERAPY | No dispute reported | 06/30/2026 | 853090087 |
| Principal investigator 1 | Roche Products Limited | $1,850.00 | 08/12/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030079 |
| Principal investigator 1 | UCB SA | $5,503.00 | 08/12/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844228443 |
| Principal investigator 1 | UCB SA | $1,275.00 | 08/12/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844229563 |
| Principal investigator 1 | UCB SA | $3,846.00 | 08/12/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844229637 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,610.00 | 08/10/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, P.A. | SECOND PHASE III IN RMS | No dispute reported | 06/30/2026 | 836030127 |
| Principal investigator 1 | Roche Products Limited | $2,497.51 | 07/22/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030071 |
| Principal investigator 1 | Roche Products Limited | $2,682.00 | 07/15/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, P.A. | PHASE II STUDY IN RRMS | No dispute reported | 06/30/2026 | 836030145 |
| Principal investigator 1 | Roche Products Limited | $700.00 | 07/08/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030067 |
| Principal investigator 1 | UCB SA | $108.56 | 06/30/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | No dispute reported | 06/30/2026 | 844226537 |
| Principal investigator 1 | UCB SA | $924.00 | 06/29/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844224699 |
| Principal investigator 1 | UCB SA | $4,203.00 | 06/29/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844224703 |
| Principal investigator 1 | UCB SA | $6,564.00 | 06/24/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844225413 |
| Principal investigator 1 | UCB SA | $1,582.00 | 05/27/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP | No dispute reported | 06/30/2026 | 844226191 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,958.00 | 05/25/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, P.A. | SECOND PHASE III IN RMS | No dispute reported | 06/30/2026 | 836030121 |
| Principal investigator 1 | UCB SA | $6,846.00 | 05/24/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844226189 |
| Principal investigator 1 | UCB SA | $2,406.00 | 05/17/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844226575 |
| Principal investigator 1 | Roche Products Limited | $2,682.00 | 05/11/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, P.A. | PHASE II STUDY IN RRMS | No dispute reported | 06/30/2026 | 836030139 |
| Principal investigator 1 | UCB SA | $9,966.00 | 04/22/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844224577 |
| Principal investigator 1 | UCB SA | $11,031.75 | 04/22/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP | No dispute reported | 06/30/2026 | 844226825 |
| Principal investigator 1 | Roche Products Limited | $4,140.00 | 04/19/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030061 |
| Principal investigator 1 | UCB SA | $2,549.00 | 04/15/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844224419 |
| Principal investigator 1 | UCB SA | $2,276.00 | 04/15/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP | No dispute reported | 06/30/2026 | 844224421 |
| Principal investigator 1 | UCB SA | $1,346.29 | 04/14/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS | No dispute reported | 06/30/2026 | 844224053 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,247.20 | 04/07/2021 | Non-covered Recipient Entity NEUROLOGICAL INSTITUTE PA | LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY STARTED WITH FINGOLIMOD ONCE DAILY OR TREATED WITH ANOTHER APPROVED DISEASE MODIFYING THERAPY | No dispute reported | 06/30/2026 | 800636541 |
| Principal investigator 1 | UCB SA | $2,258.00 | 03/29/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223821 |
| Principal investigator 1 | UCB SA | $6,904.00 | 03/29/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223953 |
| Principal investigator 1 | SK Life Science, Inc. | $7,124.60 | 03/27/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A | 1-Q3RAS | No dispute reported | 06/30/2026 | 826788411 |
| Principal investigator 1 | UCB SA | $7,889.75 | 03/25/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223809 |
| Principal investigator 1 | SK Life Science, Inc. | $500.00 | 03/23/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A | 1-Q3RAS | No dispute reported | 06/30/2026 | 826788409 |
| Principal investigator 1 | SK Life Science, Inc. | $500.00 | 03/23/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A | 1-Q3RAS | No dispute reported | 06/30/2026 | 826788423 |
| Principal investigator 1 | UCB SA | $4,009.00 | 03/18/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A. | A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( | No dispute reported | 06/30/2026 | 844223735 |
| Principal investigator 1 | UCB SA | $9,547.00 | 03/01/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223645 |
| Principal investigator 1 | Roche Products Limited | $1,850.00 | 02/25/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030049 |
| Principal investigator 1 | Roche Products Limited | $700.00 | 02/25/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030055 |
| Principal investigator 1 | UCB SA | $3,725.00 | 02/25/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223439 |
| Principal investigator 1 | UCB SA | $11,958.00 | 02/25/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223441 |
| Principal investigator 1 | UCB SA | $9,547.00 | 02/18/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223207 |
| Principal investigator 1 | UCB SA | $3,612.00 | 02/18/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy CIDP | No dispute reported | 06/30/2026 | 844223231 |
| Principal investigator 1 | UCB SA | $1,700.00 | 02/11/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A. | A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( | No dispute reported | 06/30/2026 | 844223007 |
| Principal investigator 1 | Roche Products Limited | $1,850.00 | 02/08/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030043 |
| Principal investigator 1 | UCB SA | $810.00 | 02/08/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A. | A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( | No dispute reported | 06/30/2026 | 844223005 |
| Principal investigator 1 | UCB SA | $5,188.00 | 02/08/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223043 |
| Principal investigator 1 | UCB SA | $1,702.00 | 02/08/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844223143 |
| Principal investigator 1 | UCB SA | $9,730.30 | 01/28/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844222655 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $76,196.86 | 01/25/2021 | Non-covered Recipient Entity NEUROLOGICAL INSTITUTE | AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS | No dispute reported | 06/30/2026 | 800636535 |
| Principal investigator 1 | Roche Products Limited | $2,497.51 | 01/18/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030037 |
| Principal investigator 1 | UCB SA | $5,046.00 | 01/13/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844222057 |
| Principal investigator 1 | Roche Products Limited | $981.51 | 01/07/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE PA | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SATRALIZUMAB SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA NMO AND NEUROMYELITIS OPTICA SPECTRUM DISORDER NMOSD | No dispute reported | 06/30/2026 | 836030031 |
| Principal investigator 1 | UCB SA | $1,614.00 | 01/07/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE, PA | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 844222193 |
| Principal investigator 1 | UCB SA | $1,218.75 | 01/07/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A. | A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( | No dispute reported | 06/30/2026 | 844222971 |
| Principal investigator 1 | UCB SA | $1,700.00 | 01/07/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A. | A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY | No dispute reported | 06/30/2026 | 844222973 |
| Principal investigator 1 | UCB SA | $220.00 | 01/07/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A. | A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY | No dispute reported | 06/30/2026 | 844222975 |
| Principal investigator 1 | UCB SA | $336.00 | 01/04/2021 | Non-covered Recipient Entity THE NEUROLOGICAL INSTITUTE P.A. | A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF UCB7665 IN SUBJECTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY ( | No dispute reported | 06/30/2026 | 844222977 |